HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

2nd Edition of International Conference

and Expo on Clinical Microbiology

June 23-24, 2023 | Rome, Italy

ICCM 2022

Muhammad Morshed

Speaker at Clinical Microbiology 2022 - Muhammad Morshed
University of British Columbia, Canada
Title : Utilization of SARS CoV 2 serology in Public Health and Clinical Uses


The SARS-CoV-2 virus causes COVID-19 disease, which was first diagnosed in late December 2019 among a few people with unknown respiratory illness in Wuhan city, Hubei province, China.  Presumably this virus jumped from a natural host to human, and that occurred in one of the open food markets in Wuhan city, spreading very quickly to neighbouring provinces, neighbouring countries and eventually different continents. The World Health Organization declared the outbreak a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020. This virus killed over 5.5 million people globally as of 2021 and there is no sign of stopping with the latest addition of Omicron variant. However; SARS CoV-2 also forced us to invent new skills and technology not only to defeat it but also to propel ourselves forward. For instance, serological diagnostic tests in the form of Point of Care Test (POCT) format and regular EIA format become available in a couple of months instead of years.
Although molecular/ RT PCR become the test of choice for clinical diagnosis, serology has also limited uses for patient care in addition to Public Health (PH) uses. For PH, SARS-CoV-2 antibody testing is testing is essential for estimating population based seroprevalence and also to assess vaccine efficacy or responses which enable evidence-based decision making for public health recommendations. For clinical care, SARS CoV-2 antibody testing help select group of population where molecular/PCR test is negative. So it may help to increase case identification when used as an adjunct to routine molecular testing in those select cohorts; however, it is become challenging due to the emergence of new variants. So, in this presentation we will review serological testing of patients’ blood against SARS Cov-2 virus and highlight pros and cons of uses of serological testing in public health and its uses of clinical diagnosis.


Dr. Morshed is a public health clinical microbiologist at the BCCDC Public Health Laboratory in Vancouver, British Columbia, Vancouver, Canada, where he is Head of the Zoonotic and Emerging Pathogens section since 1997. He is also a Clinical Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. His area of interest is spirochaetal disease such as syphilis and Lyme disease and also working on serological aspects of SARS CoV-2.  He has also added significantly to the general knowledge and understanding of these diseases with more than 140 refereed scientific publications. On his recognition, Dr. Morshed received an Excellence in Clinical Services Award from UBC’s Department of Pathology & Laboratory Medicine in 2016, RBC Top 25 Canadian Immigrant Awards in 2017; Distinguished Microbiologists Award by the Canadian College of Microbiologists in 2019 and elected as an Expatriate Fellow of the Bangladesh Academic of Sciences in 2020.